药物释放型支架市场（按类型、药物、应用、最终用户和分销管道）—全球预测 2025-2032

预计到 2032 年药物释放型支架市场规模将成长至 187.6 亿美元，复合年增长率为 11.15%。

主要市场统计数据
基准年2024年	80.5亿美元
预计2025年	89.3亿美元
预测年份：2032年	187.6亿美元
复合年增长率（%）	11.15%

全面介绍药物释放型支架的临床相关性、设备演变、监管途径和策略要点

药物释放型支架已成为介入性心臟病学和血管医学的关键治疗性介入，并被纳入多种动脉粥状硬化疾病的现代治疗途径。在过去的二十年中，这些装置已从第一代设计发展成为能够平衡抗增殖药物传输与复杂支架和聚合物技术的精密平台。这一发展得益于生物相容性、输送能力和临床疗效的不断改进，以及随机试验和真实世界註册研究中持续不断的证据生成。

临床医生和采购主管现在必须应对这样一个情况：器械选择会影响手术成功率、长期血管通畅性以及下游资源利用率。因此，了解器械设计、药物动力学、聚合物行为和临床适应症之间的相互作用，对于优化患者护理和机构绩效至关重要。同时，监管监督和付款方需求正将重点转向可证明的安全性和长期有效性，促使製造商强调上市后数据和差异化的临床声明。在此背景下，本摘要概述了医院、门诊中心和分销通路相关人员决策时需要考虑的策略、临床和商业性因素。

分析重新定义涂药支架领域患者治疗结果和市场动态的技术、临床和商业性变革

技术、临床和市场力量的融合正在再形成药物释放型支架的格局，这些力量共同推动着改变。材料科学的进步使得更薄的支架设计和更俱生物相容性的涂层成为可能，而这些硬体改进与药物配方的创新相辅相成，旨在优化局部抗增殖效果，同时最大限度地降低全身暴露。因此，器械的差异化越来越依赖细微的性能特征，例如内皮癒合特性、在复杂解剖结构中的输送能力以及与辅助影像和生理评估工具的兼容性。

同时，临床实践也在不断发展。外科医生越来越多地将血管内成像和生理引导纳入其常规工作流程，从而改变了器械选择标准和手术方法。这种精准支架置入的趋势为在影像引导下表现出可预测和可重复行为的支架平台提供了机会。从商业性角度来看，医疗保健系统越来越重视护理总成本和长期疗效，从而凸显了强有力的上市后证据和基于价值的合约的重要性。此外，随着专业创新者推出利基设计，而老牌製造商追求产品组合广度和生命週期管理，竞争态势正在加剧。监管预期也同样不断增强，更加重视长期安全数据和真实世界疗效，促使製造商投资于纵向註册和自适应试验设计。总而言之，这些转变正在重新定义临床价值的展示方式、产品的采购方式以及公司如何优先安排其研发和上市活动。

2025 年美国关税的详细评估及其对供应链、筹资策略和药物释放型支架取得的影响

2025年美国加征关税可能会波及全球医疗设备供应链，对采购、库存管理及筹资策略有具体影响。其初期影响将最显着地体现在受关税上调影响的跨境製造投入和成品器械上，促使采购机构重新评估其供应商布局，并在成本、前置作业时间和供应商可靠性之间进行权衡。为此，一些医疗系统将扩大供应商基础，优先考虑具有本地製造能力的供应商，或协商合约保护措施，以缓解短期价格波动。

在营运层面，医疗设备製造商和经销商可能会重新评估其物流策略，强调替代路线、区域仓储和多方采购，以维持供应的连续性。此类调整可能会导致更长的规划週期和更高的营运成本，尤其是对于高价值植入式医疗设备而言。此外，采购团队可能会调整其竞标评估框架，将与关税相关的成本差异和供应链弹性指标纳入考量，从而改变那些成本基础更容易受到关税影响的供应商的竞争定位。

在临床方面，相关人员必须确保采购变更不会损害器械品质或临床疗效。这需要严格的供应商资格确认、快速检验替代製造地，以及在医院和门诊中心层级谨慎管理器械过渡通讯协定。从创新角度来看，关税可以增强本地生产和技术转移的奖励，加速对国内製造能力的投资以及向地区监管机构的备案。最终，虽然关税可能会造成短期中断和成本压力，但它们也会催化策略转变，影响製造商和医疗保健系统对韧性、供应商关係以及製造业地理分布的思考。

细分洞察揭示了类型、药物、应用、最终用户和分销细微差别如何影响临床选择、采购优先事项和商业化

药物释放型支架市场细分领域的差异化驱动着临床决策和商业策略，而对支架类型、药物、应用、最终用户和分销管道的综合考虑对于理解其应用动态至关重要。就器械类型而言，市场分为聚合物涂层系统和非聚合物涂层平台。在聚合物涂层产品中，市场进一步细分为旨在随时间推移吸收的可生物降解聚合物涂层设计和可长期保持涂层特性的耐用聚合物涂层结构。这些差异会影响癒合生物学、远期不利事件概况以及向关注长期血管通畅性的临床医生讯息。

药物选择是另一个差异化因素，目前已有多种可用于洗脱药物的设备，例如比奥莫司、Everolimus、紫杉醇和Sirolimus。每种药物的药理效力、组织滞留特性和先前依证均有所不同，这会影响针对特定病变类型和患者风险群的设备定位。冠状动脉疾病的临床需求和表现预期与週边血管疾病不同，当操作人员处理复杂的周边解剖结构或寻求持续改善肢体灌注时，设备属性的权重也不同。

最终用户也决定购买和使用模式。同时，门诊手术中心优先考虑那些能够提高效率、可预测结果和缩短工作流程的设备。最后，分销管道决定了获取和采购路径。医院药局、线上药局平台和零售药局各自呈现出不同的路线、库存和报销考量，这些考量会影响设备如何到达照护现场。综合起来，这些细分揭示了产品开发的重点、证据生成计划和商业化策略，凸显了製定能够引起不同医疗环境中临床医生、供应链经理和付款人共鸣的客製化价值命题主张的必要性。

区域动态决定了不同医疗体系和经济体中药物释放型支架的临床采用、购买行为和报销方式

区域动态对药物释放型支架的采用、报销以及纳入医疗路径的方式有着重大影响，了解这些差异对于跨国策略和区域商业化计画至关重要。在美洲，公立和私立支付机构的报销框架各不相同，采购者在评估新的支架平台时通常会强调比较临床数据和手术经济学。采购週期可以集中在医院网路内，也可以分散在各个机构之间，这些差异决定了製造商的价值主张以及供应协议的谈判方式。

欧洲、中东和非洲地区的市场模式差异巨大，已开发国家和新兴欧洲国家的监管环境、报销时限和临床实务模式有显着差异。在该地区的许多司法管辖区，卫生技术评估结果和国家采购计划在市场准入决策中发挥着重要作用，因此製造商必须考虑建立区域合作伙伴关係，以使临床证据方案与付款方预期相符，并加快市场准入。

亚太地区介入手术的成长伴随着多样化的监管途径和参差不齐的本地製造能力。一些市场优先考虑高性价比的设备，并迅速采用能够提升通量和疗效的技术；而其他市场则强调国内产业的发展和在地化。在每个地区，临床培训、血管内成像的可用性以及医院报销结构之间的相互作用决定了设备的选择以及新平台的采用速度。因此，在证据产生、定价和相关人员参与方面采取细緻入微的区域性方法，对于最大限度地提高临床应用率并解决本地系统的限制至关重要。

临床、监管和付款人变化背景下药物释放型支架开发和商业化公司的竞争状况和策略重点

药物释放型支架公司之间的竞争动态取决于产品创新、证据产生以及展示永续临床和经济价值的能力。成熟的製造商通常利用广泛的产品组合、全球监管批准和丰富的上市后资料集来保持领先地位，而专业的创新企业则专注于差异化的设计特征和利基适应症，为临床应用铺平道路。那些在稳健的临床计画和有针对性的真实世界证据收集之间取得平衡的公司，往往能够透过兼顾疗效和长期安全性问题，更有效地影响购买决策。

对于寻求整合互补能力（例如设备工程、配方专业知识和区域市场准入）的公司而言，伙伴关係和策略联盟正变得越来越重要。供应链弹性已成为核心策略重点，製造商正在实现生产基地多元化，检验关键零件的多个供应商，并投资于支援快速扩大规模的品质系统。从商业性角度来看，提供全面培训、实施支援和数据主导提案主张的公司正日益受到注重流程一致性和优化结果的医院系统的青睐。总而言之，为了保持竞争优势，市场领导者和竞争者都必须使其研发投资、证据策略和供应链计画与临床医生、医疗系统和付款人不断变化的期望保持一致。

为领导者提供实用建议，以加速涂药支架领域的创新、优化采购并改善临床和商业性结果

产业领导者可以采取具体行动，加速创新，保障供应连续性，巩固商业性地位，同时改善病患治疗效果。首先，优先制定清晰的证据蓝图，将随机临床试验和可操作的註册库结合起来，既能满足监管要求，又能解决临床医生和付款人的实际担忧。其次，投资于供应链多元化，包括区域製造能力和关键投入的有效二级供应商，将降低贸易中断带来的脆弱性，并支持与大型医疗系统进行更可预测的采购对话。

第三，将产品设计与影像引导介入和新兴治疗途径的实际情况结合，将增强临床差异化。在註重精准医疗的环境中，能够清晰地促进血管内成像、可预测部署和一致癒合曲线的平台将更具吸引力。第四，製造商应扩展其商业模式，在可行的情况下纳入基于价值的合同试点和与结果挂钩的合同，从而与卫生系统的优先事项更加紧密地协调一致。最后，临床医生教育和应用支援，例如程序培训和数据共用计划，可以提高采用率并优化实际应用效果。透过以整合的方式实施这些措施，产业领导者可以平衡当前的业务挑战和长期创新目标。

调查方法，总结了临床文献综合、专家相关人员参与、数据检验和药物释放型支架研究中使用的分析技术。

该报告的研究结果基于一种多方法调查方法，该方法整合了临床文献、专家相关人员的见解和检验的数据来源。分析过程始于对同行评审的临床研究、指南文件和监管文件进行系统性回顾，以建立支架技术的临床性能基准。除了次要分析之外，我们还与介入性心臟病专家、血管专家、采购负责人和分销合作伙伴进行了结构化访谈和咨询，以了解该领域对器械选择、操作流程和供应链约束的观点。

原始资料收集包括有针对性的定性访谈和去识别化程序登记册的审查，以检验文献中观察到的模式。透过将临床结果与相关人员的回馈和操作考量进行交叉引用，进行资料三角测量和检验，并透过记录纳入标准、访谈通讯协定和资料清理流程来保持调查方法透明度。在适用的情况下，结果会根据法律规范和报销惯例进行具体分析，以确保所提供的见解既能反映临床实际情况，又能反映商业性需求。

结论性综合报告强调了策略重点、创新需求以及改善病患治疗效果和医疗产业復原力的协作行动

综上所述，药物释放型支架领域正处于曲折点，其驱动力来自材料科学的进步、临床实践的演变以及商业性预期的不断变化。持续的差异化将取决于此器材平台能否展现出具有临床意义的改进，同时又能适应现代介入治疗的程序性现实。同时，贸易政策的变化以及对弹性供应链的需求等外部压力将影响采购行为和产品供应，这给製造商和医疗保健系统带来了挑战和策略机会。

为了应对这种环境，相关人员必须采取一种协作的方式，将强大的证据生成、营运韧性和周到的商业化相结合。临床领导者应继续采用影像引导和生理主导的实践，采购团队应将供应链风险纳入采购框架，製造商应追求以令人信服的真实世界数据为支撑的重点创新。这种整体方向将有助于确保设备技术的进步转化为患者照护的持续改善，并为医疗保健系统带来持久的价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 可生物降解聚合物药物释放型支架的出现降低了晚期支架血栓症的风险
• 越来越多地采用光学同调断层扫描进行血管内影像引导，以优化药物释放型支架的放置
• 过渡到超薄支柱药物释放型支架可提高输送能力并减少放置后的动脉创伤。
• 采用微储库技术控制释放抗增殖药物的无聚合物药物释放型支架的出现
• 由于心血管疾病盛行率上升和保险报销范围扩大，亚太地区和拉丁美洲的需求正在增加。
• 医疗设备製造商与生物製药公司合作开发下一代整合平台
• 重视长期真实世界证据研究，检验第二代药物释放型支架的安全性和有效性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章药物释放型支架市场（按类型）

• 聚合物涂层
  • 可生物降解聚合物涂层
  • 耐用的聚合物涂层
• 不含聚合物

第九章药物释放型支架市场（按药物）

• Biolimus洗脱
• Everolimus洗脱
• 紫杉醇洗脱
• Sirolimus洗脱

第 10 章药物释放型支架市场（依应用）

• 冠状动脉疾病
• 周围血管疾病

第 11 章药物释放型支架市场（依最终用户）

• 门诊手术中心
• 医院

第十二章药物释放型支架市场（依分销管道）

• 医院药房
• 网路药局
• 零售药局

第十三章药物释放型支架市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章药物释放型支架市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章药物释放型支架市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Terumo Corporation
  • BIOTRONIK AG
  • MicroPort Scientific Corporation
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Meril Life Sciences Private Limited
  • Biosensors International Group, Ltd.
  • Johnson & Johnson

The Drug Eluting Stent Market is projected to grow by USD 18.76 billion at a CAGR of 11.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 8.05 billion
Estimated Year [2025]	USD 8.93 billion
Forecast Year [2032]	USD 18.76 billion
CAGR (%)	11.15%

Comprehensive introduction outlining clinical relevance, device evolution, regulatory pathways, and strategic imperatives shaping adoption of drug eluting stents

Drug eluting stents have become a pivotal therapeutic intervention in interventional cardiology and vascular medicine, embedding themselves within modern treatment pathways for a range of atherosclerotic conditions. Over the past two decades, these devices have evolved from first-generation designs into sophisticated platforms that balance antiproliferative drug delivery with refined scaffold and polymer technology. This evolution has been driven by iterative improvements in biocompatibility, deliverability, and clinical outcomes, and by a continuous cycle of evidence generation across randomized trials and real-world registries.

Clinicians and procurement leaders now must navigate a landscape in which device choice influences procedural success, long-term vessel patency, and downstream resource utilization. As such, understanding the interplay of device design, drug kinetics, polymer behavior, and clinical indication is central to optimizing patient care and institutional performance. Simultaneously, regulatory scrutiny and payer requirements have shifted priorities toward demonstrable safety and long-term effectiveness, prompting manufacturers to emphasize post-market data and differentiated clinical claims. In this context, the present summary frames the strategic, clinical, and commercial considerations that underpin decision making for stakeholders across hospitals, ambulatory centers, and distribution channels.

Analysis of transformative technological, clinical, and commercial shifts redefining patient outcomes and market dynamics within the drug eluting stent landscape

The drug eluting stent landscape is being reshaped by converging technological, clinical, and market forces that together constitute transformative change. Advances in materials science have enabled thinner strut designs and more biocompatible coatings, and these hardware refinements are complemented by innovations in drug formulation that aim to optimize local antiproliferative effects while minimizing systemic exposure. As a result, device differentiation increasingly rests on nuanced performance characteristics such as endothelial healing profiles, deliverability in complex anatomies, and compatibility with adjunctive imaging and physiologic assessment tools.

Concurrently, clinical practice is evolving: operators are integrating intravascular imaging and physiologic guidance into routine workflows, which alters device selection criteria and procedural approaches. This trend toward precision deployment is creating opportunities for stent platforms that demonstrate predictable and reproducible behavior under image-guided techniques. From a commercial perspective, healthcare systems are emphasizing total cost of care and long-term outcomes, which elevates the importance of robust post-market evidence and value-based contracting. Additionally, the competitive dynamic is intensifying as specialized innovators introduce niche designs while established manufacturers pursue portfolio breadth and lifecycle management. Regulatory expectations have likewise become more rigorous, with stronger emphasis on longer-term safety data and real-world performance, prompting manufacturers to invest in longitudinal registries and adaptive study designs. Taken together, these shifts are redefining how clinical value is demonstrated, how products are procured, and how companies prioritize R&D and market access activities.

In-depth assessment of United States tariff actions in 2025 and their effects on supply chains, procurement strategies, and access to drug eluting stents

The imposition of United States tariff measures in 2025 has the potential to reverberate across global supply chains for medical devices, creating tangible implications for procurement, inventory management, and sourcing strategies. Early effects are most pronounced where manufacturing inputs or finished devices cross borders subject to increased duties, prompting purchasing organizations to reassess supplier footprints and to evaluate the tradeoffs between cost, lead time, and supplier reliability. In response, some health systems may broaden their supplier base, prioritize vendors with local manufacturing capabilities, or negotiate contractual protections to mitigate short-term price volatility.

At the operational level, device manufacturers and distributors are likely to revisit logistics strategies, increasing the emphasis on alternative routing, regional warehousing, and multi-sourcing to preserve continuity of supply. These adjustments can lengthen planning cycles and raise working capital requirements, particularly for high-value implantable devices. Moreover, procurement teams may adjust tender evaluation frameworks to incorporate duty-related cost differentials and supply chain resilience metrics, thereby altering competitive positioning for suppliers whose cost base is sensitive to tariff exposure.

Clinically, stakeholders will need to ensure that any shifts in sourcing do not compromise device quality or clinical outcomes. This necessitates rigorous supplier qualification, accelerated validation of alternative manufacturing sites, and careful management of device transition protocols at the hospital and ambulatory center level. From an innovation standpoint, tariffs can increase incentives for local production and technology transfer, potentially accelerating investments in domestic manufacturing capacity and in-region regulatory submissions. Ultimately, while tariffs may create near-term disruption and cost pressure, they also catalyze strategic shifts that influence how manufacturers and health systems think about resilience, supplier relationships, and geographic diversification of manufacturing.

Segmentation insights revealing how type, drug, application, end user, and distribution nuances drive clinical choice, procurement priorities, and commercialization

Segment-level differentiation in the drug eluting stent space drives both clinical decision making and commercial strategy, and an integrated view of type, drug, application, end user, and distribution channel is essential to appreciate adoption dynamics. Regarding device type, the market distinguishes between polymer coated systems and polymer free platforms; within polymer coated offerings, there is a further split between biodegradable polymer coated designs that aim to resorb over time and durable polymer coated constructs that retain their coating profile long term. These distinctions influence healing biology, late adverse event profiles, and messaging for clinicians focused on long-term vessel patency.

Drug selection represents another axis of differentiation, with devices eluting agents such as biolimus, everolimus, paclitaxel, and sirolimus. Each drug differs in pharmacologic potency, tissue retention characteristics, and historical evidence base, which affects device positioning for specific lesion types and patient risk cohorts. Application context matters as well: the clinical needs and performance expectations for coronary artery disease differ from those for peripheral vascular disease, and device attributes are weighed differently when operators manage challenging peripheral anatomies or seek durable improvement in limb perfusion.

End users also frame purchasing and utilization patterns. Hospitals typically drive higher procedural volumes and manage complex cases requiring a broad set of device options and rapid supply availability, whereas ambulatory surgical centers focus on efficiency, predictable outcomes, and devices that facilitate short-stay workflows. Finally, distribution channels shape access and procurement pathways: hospital pharmacies, online pharmacy platforms, and retail pharmacies each present distinct routing, inventory, and reimbursement considerations that affect how devices reach point-of-care. Taken together, these segmentation dimensions inform product development priorities, evidence generation plans, and commercialization strategies, and they underscore the need for tailored value propositions that resonate with clinicians, supply chain managers, and payers across diverse care settings.

Regional dynamics that determine clinical adoption, purchasing behavior, and reimbursement approaches for drug eluting stents across diverse healthcare systems and economies

Regional dynamics materially influence how drug eluting stents are adopted, reimbursed, and integrated into care pathways, and understanding these differences is critical for multinational strategy and for localized commercialization plans. In the Americas, reimbursement frameworks vary across public and private payers, and purchasers often emphasize comparative clinical data and procedural economics when evaluating new stent platforms. Procurement cycles can be centralized within hospital networks or decentralized across individual institutions, and this variability shapes how manufacturers present value and negotiate supply agreements.

Across Europe, Middle East & Africa the landscape is heterogeneous, with regulatory processes, reimbursement timelines, and clinical practice patterns differing significantly between advanced European markets and emerging economies. In many jurisdictions within this region, health technology assessment outcomes and national procurement programs play an outsized role in determining market access, which requires manufacturers to align clinical evidence packages with payer expectations and to consider regional partnerships to expedite market entry.

In Asia-Pacific, growth in interventional procedures is accompanied by diverse regulatory pathways and varying levels of local manufacturing capability. Some markets prioritize cost-effective devices and demonstrate rapid adoption of technologies that deliver demonstrable improvements in throughput and outcomes, whereas others emphasize domestic industry development and localization. Across all regions, the interplay of clinical training, availability of intravascular imaging, and the structure of hospital reimbursement shapes device selection and the pace at which new platforms gain traction. Therefore, a regionally nuanced approach to evidence generation, pricing, and stakeholder engagement is essential to maximize clinical uptake and to address local system constraints.

Competitive profiles and strategic priorities for companies developing and commercializing drug eluting stents amid clinical, regulatory, and payer shifts

Competitive dynamics among companies engaged with drug eluting stents are defined by product innovation, evidence generation, and the ability to demonstrate sustainable clinical and economic value. Established manufacturers typically leverage broad portfolios, global regulatory clearances, and extensive post-market datasets to maintain leadership, while specialized innovators focus on differentiated design features or niche indications to create pathways for clinical adoption. Firms that balance robust clinical programs with targeted real-world evidence collection tend to influence purchasing decisions more effectively because they can address both efficacy and longer-term safety concerns.

Partnerships and strategic alliances are increasingly important as companies seek to combine complementary capabilities, such as device engineering, drug formulation expertise, and regional market access. Supply chain resilience has become a core strategic priority, prompting manufacturers to diversify production footprints, validate multiple suppliers for critical components, and invest in quality systems that support rapid scaling. Commercially, companies that offer comprehensive training, implementation support, and data-driven value propositions find greater receptivity among hospital systems focused on procedural consistency and outcome optimization. In sum, market leaders and challengers alike must align R&D investments, evidence strategies, and supply chain planning with the shifting expectations of clinicians, health systems, and payers to sustain competitive advantage.

Practical recommendations for leaders to accelerate innovation, optimize procurement, and improve clinical and commercial outcomes in the drug eluting stent space

Industry leaders can take concrete actions to accelerate innovation, safeguard supply continuity, and strengthen commercial positioning while improving patient outcomes. First, prioritizing a clear evidence roadmap that couples randomized clinical studies with pragmatic registries will address both regulatory requirements and the practical concerns of clinicians and payers. Second, investing in supply chain diversification, including regional manufacturing capabilities and validated secondary suppliers for critical inputs, will reduce vulnerability to trade disruptions and support more predictable procurement conversations with large health systems.

Third, aligning product design with the realities of image-guided intervention and emerging care pathways will enhance clinical differentiation; platforms that demonstrably facilitate intravascular imaging, predictable deployment, and consistent healing profiles will be more attractive in settings that demand precision. Fourth, manufacturers should expand commercial models to include value-based contracting pilots and outcome-linked agreements where feasible, enabling closer alignment with health system priorities. Finally, advancing clinician education and deployment support, including procedural training and data-sharing initiatives, will improve uptake and optimize real-world performance. By executing these measures in an integrated manner, industry leaders can balance immediate operational challenges with longer term innovation goals.

Methodology summarizing clinical literature synthesis, expert stakeholder engagement, data validation, and analytical techniques used in drug eluting stent studies

This report's findings are rooted in a multi-method research approach that synthesizes clinical literature, expert stakeholder insights, and validated data sources. The analytical process began with systematic reviews of peer-reviewed clinical studies, guideline documents, and regulatory submissions to establish the clinical performance benchmarks for stent technologies. These secondary-source analyses were complemented by structured interviews and consultations with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture frontline perspectives on device selection, procedural workflow, and supply chain constraints.

Primary data collection included targeted qualitative interviews and the review of anonymized procedural registries to validate patterns observed in the literature. Data triangulation and validation were performed through cross-referencing clinical outcomes with stakeholder feedback and operational considerations, and methodological transparency was maintained by documenting inclusion criteria, interview protocols, and data-cleaning processes. Wherever applicable, results were contextualized against regulatory frameworks and reimbursement practices to ensure that the insights provided reflect both clinical realities and commercial imperatives.

Concluding synthesis stressing strategic priorities, innovation imperatives, and coordinated actions to improve patient outcomes and sector resilience

In synthesis, the drug eluting stent domain is at an inflection point driven by material science advances, evolving clinical practice, and shifting commercial expectations. Continued differentiation will depend on the ability of device platforms to demonstrate clinically meaningful improvements while fitting into the procedural realities of modern interventional practice. At the same time, external pressures such as trade policy changes and the demand for resilient supply chains will influence procurement behavior and product availability, creating both challenges and strategic opportunities for manufacturers and health systems.

To navigate this environment, stakeholders must adopt a coordinated approach that marries robust evidence generation with operational resilience and thoughtful commercialization. Clinical leaders should continue to embrace image-guided and physiology-driven practices, procurement teams must incorporate supply chain risk into purchasing frameworks, and manufacturers need to pursue focused innovation supported by compelling real-world data. This holistic orientation will help ensure that advances in device technology translate into sustained improvements in patient care and durable value for healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of biodegradable polymer drug eluting stents reducing late stent thrombosis risk
• 5.2. Increasing adoption of intravascular imaging guidance with optical coherence tomography to optimize drug eluting stent placement
• 5.3. Shift toward ultrathin strut drug eluting stents enhancing deliverability and reducing arterial injury post implantation
• 5.4. Emergence of polymer free drug eluting stents with microreservoir technology for controlled antiproliferative drug release
• 5.5. Growing demand in Asia Pacific and Latin America driven by rising cardiovascular disease prevalence and expanded reimbursement
• 5.6. Collaboration between medical device manufacturers and biopharmaceutical companies for next generation combination drug eluting stent platforms
• 5.7. Escalating focus on long term real world evidence studies to validate safety and efficacy of second generation drug eluting stents

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Stent Market, by Type

• 8.1. Polymer Coated
  • 8.1.1. Biodegradable Polymer Coated
  • 8.1.2. Durable Polymer Coated
• 8.2. Polymer Free

9. Drug Eluting Stent Market, by Drug

• 9.1. Biolimus Eluting
• 9.2. Everolimus Eluting
• 9.3. Paclitaxel Eluting
• 9.4. Sirolimus Eluting

10. Drug Eluting Stent Market, by Application

• 10.1. Coronary Artery Disease
• 10.2. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Drug Eluting Stent Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Drug Eluting Stent Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Drug Eluting Stent Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. Boston Scientific Corporation
  • 16.3.3. Medtronic plc
  • 16.3.4. Terumo Corporation
  • 16.3.5. BIOTRONIK AG
  • 16.3.6. MicroPort Scientific Corporation
  • 16.3.7. Lepu Medical Technology (Beijing) Co., Ltd.
  • 16.3.8. Meril Life Sciences Private Limited
  • 16.3.9. Biosensors International Group, Ltd.
  • 16.3.10. Johnson & Johnson

LIST OF FIGURES

• FIGURE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRUG ELUTING STENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 111. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 113. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 117. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 119. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 126. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 128. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 132. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 134. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 140. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 141. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 142. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 146. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 148. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 179. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 182. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 184. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 188. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 193. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 196. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 197. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 198. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 201. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 202. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 207. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 210. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 211. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 212. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 226. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 227. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 228. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 240. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 241. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 242. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 243. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 244. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 245. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 246. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 247. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 248. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 249. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 250. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 251. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 259. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 260. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 261. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 265. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 268. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 269. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 270. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 271. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 272. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 273. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 274. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 275. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 277. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 278. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 279. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 280. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 281. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 282. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 283. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 284. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 285. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 286. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 287. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 288. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 289. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 291. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 296. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 297. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 298. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 299. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 300. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 301. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 302. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 303. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 307. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 308. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 309. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 310. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 311. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 312. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 313. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 314. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 315. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 316. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 317. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 318. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 319. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 320. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 321. CANADA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 322. CANADA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 323. CANADA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 324. CANADA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 325. CANADA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 326. CANADA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 327. CANADA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 328. CANADA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 329. CANADA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 330. CANADA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 331. CANADA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. CANADA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 333. MEXICO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 334. MEXICO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
• TABLE 335. MEXICO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
• TABLE 336. MEXICO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
• TABLE 337. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
• TABLE 338. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
• TABLE 339. MEXICO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 340. MEXICO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 341. MEXICO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 342. MEXICO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 343. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 344. MEXICO DRUG E